The markets opened mixed with the Dow losing 41 points to 20,861 while Nasdaq rose 8 points to 5,870 ahead of the Federal Reserve meeting tomorrow.
On the upside
Mobileye (NYSE: MBLY) will be acquired by Intel (Nasdaq: INTC) for a premium of approximately $15.3 billion.
Fate Therapeutics (Nasdaq: FATE) received clearance from the Food and Drug Administration for its investigational new drug application for FATE-NK100.
Verastem (Nasdaq: VSTM) will present at the 29th Annual ROTH Conference today.
On the downside
Catabasis Pharmaceuticals (Nasdaq: CATB) will present data from Part B of the MoveDMD trial of edasalonexent to treat Duchenne muscular dystrophy at the 2017 Muscular Dystrophy Association Scientific Conference next week.
Aralez Pharmaceutical (Nasdaq: ARLZ) widened losses for the fourth quarter.
Investors locked in profits on Cerecor (Nasdaq: CERC).
In the broad market, advancing issues outpaced decliners by a margin of nearly 5 to 3 on the NYSE and by more than 7 to 5 on Nasdaq. The broader S&P 500 index eased a fraction to 2,371. Bitcoin gained $13 to $1,230.